GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Vimian Group AB (FRA:0V0) » Definitions » Risk Assessment

Vimian Group AB (FRA:0V0) Risk Assessment


View and export this data going back to 2021. Start your Free Trial

What is Vimian Group AB Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Vimian Group AB is: Moderate Risk: Sensitive, better choose undervalued stock.


Competitive Comparison of Vimian Group AB's Risk Assessment

For the Diagnostics & Research subindustry, Vimian Group AB's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vimian Group AB's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Vimian Group AB's Risk Assessment falls into.


;
;

Vimian Group AB  (FRA:0V0) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.


Vimian Group AB Risk Assessment Related Terms

Thank you for viewing the detailed overview of Vimian Group AB's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.


Vimian Group AB Business Description

Traded in Other Exchanges
Address
Riddargatan 19, Stockholm, SWE, SE-11457
Vimian Group AB specializes in the areas of animal health such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription and non-prescription treatments for preventive care, and treatment of chronic conditions for companion animals, with a strong position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.

Vimian Group AB Headlines

No Headlines